Healthcare Is Sickly, But These Yields up to 7% May Still Have a Pulse

Healthcare stocks have significantly underperformed the broader market since April, presenting contrarian income opportunities with yields reaching 7.1%. This includes high-yielding healthcare REITs like Omega Healthcare Investors (OHI) and LTC Properties (LTC), which are navigating operational improvements and strategic shifts, alongside pharmaceutical blue chips such as Bristol-Myers Squibb (BMY) and Pfizer (PFE), which face patent cliffs and regulatory headwinds but offer attractive valuations and substantial dividends. Despite sector-specific uncertainties, the article highlights these names as potentially undervalued assets for investors seeking yield and long-term value.

Analysis

The healthcare sector has markedly lagged the broader market, remaining flat since early April while the S&P 500 appreciated 27%, creating potential contrarian opportunities for income-focused investors. This divergence is attributed to sector-specific headwinds, including political pressures on drug pricing and potential cuts to healthcare funding. Within healthcare REITs, Omega Healthcare Investors (OHI) exhibits strong operational momentum, having beaten adjusted funds from operations (AFFO) estimates and raised its full-year guidance, though its valuation at over 13 times forward AFFO is not considered deep value and its dividend has remained flat. Conversely, LTC Properties (LTC) is pursuing a higher-risk growth strategy by converting properties to RIDEA structures, which introduces operational exposure and uncertainty. In the pharmaceutical space, large-cap firms face significant challenges. Bristol-Myers Squibb (BMY) is trading at a low multiple of 7 times earnings and recently issued a beat-and-raise quarter, but has delivered a 10% total return loss over five years due to patent expirations for key drugs like Revlimid. Pfizer (PFE) appears even more distressed, with its stock hitting new lows and its yield reaching levels unseen since the Great Recession, driven by a failed drug trial, declining COVID-product sales, and a looming patent cliff for several major products. Despite a low 8x earnings multiple and a 55% payout ratio suggesting near-term dividend safety, Pfizer's turnaround depends heavily on unproven pipeline success and cost-cutting initiatives.

Key Decisions for Investors

• Consider the healthcare sector's underperformance as a contrarian entry point, but differentiate between fundamentally sound operators and those facing significant structural challenges.
• For healthcare REITs, favor names with demonstrated operational strength and positive guidance like Omega Healthcare Investors (OHI), while treating turnaround plays like LTC Properties (LTC) with caution due to the increased operational risk from its RIDEA strategy.
• In pharmaceuticals, Bristol-Myers Squibb (BMY) may represent a compelling value opportunity given its low valuation and recent positive results, whereas Pfizer (PFE) warrants extreme caution as its high yield may be a value trap reflecting numerous unresolved business headwinds.
• Investors must scrutinize high yields for sustainability, noting that Siga Technologies' (SIGA) 7.1% yield is an unreliable annual special dividend and that companies like Healthpeak Properties (DOC) have a history of significant dividend cuts despite recent increases.